ER+ breast cancers generally exhibit fewer neo-antigens and less lymphocytic infiltrate than HER2+ or TNBC subtypes, presenting a challenge that limits the potential for clinical benefit from immune checkpoint blocking therapies. Here, ERBB2 is linked to breast cancer.